{"id":45842,"date":"2022-07-06T08:01:40","date_gmt":"2022-07-06T06:01:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/"},"modified":"2022-07-06T08:01:40","modified_gmt":"2022-07-06T06:01:40","slug":"boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/","title":{"rendered":"Boehringer Ingelheim, Evotec and bioM\u00e9rieux launch Aurobac, a joint venture to fight Antimicrobial Resistance"},"content":{"rendered":"
\n

INGELHEIM, Germany & HAMBURG, Germany & MARCY-L\u2019\u00c9TOILE, France–(BUSINESS WIRE)–Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX\/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and bioM\u00e9rieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).\n<\/p>\n

<\/a><\/p>\n

\nThe resulting company, Aurobac Therapeutics SAS, will combine the best capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to cure. The aspiration is to succeed in the fight against AMR, which is a major public health threat. Having routine surgery such as caesarean sections or hip replacements may become life threatening, and complications from common diseases such as diabetes and injuries or cuts will become harder to manage because of growing resistance to antibiotics in patients.\n<\/p>\n

\n\u201cThe rise of antibiotic-resistant infections \u2013 also called antimicrobial resistance, or AMR \u2013 is indeed a looming global crisis,\u201d said Michel Pairet, Head of Boehringer Ingelheim\u2019s Innovation Unit and Member of the Board of Managing Directors. \u201cAntibiotic resistance kills about 1.27 million people globally every year1<\/sup> and it has been estimated that by 2050, as many as 10 million worldwide deaths could result from AMR2<\/sup>, making it potentially deadlier than cancer.\u201d\n<\/p>\n

\nWerner Lanthaler, CEO of Evotec added: \u201cThe grim prospect of a post-antibiotic era has many causes but only one solution: The development of new, targeted, and effective antimicrobial therapies. We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioM\u00e9rieux, to combine our complementary strengths. By leveraging Evotec\u2019s multimodality approach to infectious diseases, we are confident that Aurobac will be able to generate much-needed progress to tackle the global challenge of AMR.\u201d\n<\/p>\n

\n\u201cbioM\u00e9rieux has a strong expertise in antimicrobial resistance. We supply the most comprehensive integrated diagnostic solutions to support an appropriate use of antibiotics (antimicrobial stewardship),\u201d said Alexandre M\u00e9rieux, bioM\u00e9rieux Chairman and CEO. \u201cOur role within the joint venture is to develop and commercialize diagnostic tests, including Companion Diagnostics, which deliver rapid, reliable and actionable results. This participation in Aurobac is perfectly aligned with bioM\u00e9rieux\u2019 full commitment to sustain antibiotic efficacy for future generations.\u201d\n<\/p>\n

\nAurobac will work to shift the strategy related to antibiotic treatment regimens which at the moment leans heavily on empirical approaches using broad-spectrum and unfocused medicines. The goal is to turn this into a precision approach, using new highly effective and targeted modalities, combined with rapid and actionable diagnostics to quickly identify pathogens and their resistance patterns, and supported by new economic models.\n<\/p>\n

\nFunded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioM\u00e9rieux with 5 million EUR each, the 40 million EUR joint venture, which has its headquarters in Lyon (France), combines the world leading expertise of Evotec, one of the most active research companies in infectious diseases, with bioM\u00e9rieux\u2019s market-leading expertise in infectious disease diagnostics and with Boehringer Ingelheim\u2019s broad drug discovery and significant clinical development capabilities.\n<\/p>\n

\nThree partners committed to combat AMR<\/b>\n<\/p>\n

\nBoehringer Ingelheim\u2019s participation in Aurobac is part of a wider so-called pandemic preparedness initiative, which includes a 50 million EUR investment in the AMR action fund by Boehringer Ingelheim. Boehringer Ingelheim Venture Fund has committed to invest up to 12 million EUR in AMR infection companies.\n<\/p>\n

\nbioM\u00e9rieux has over 55 years of diagnostics expertise with more than 75 percent of its research and development budget focused on antimicrobial resistance. Moreover, 80 percent of its turnover is related to the fight against AMR through a complete diagnostic solution facilitating antibiotic therapy decision-making, including antibiotic initiation, optimization, and discontinuation.\n<\/p>\n

\nEvotec has built a world-leading platform to tackle infectious diseases. With a more than 200-strong anti-infective discovery team, the company has proven experience on multiple agent classes. On top of the company\u2019s own pre-competitive pandemic preparedness and rapid response technology platform (\u201cPRROTECT\u201d), Evotec leverages its infectious disease capabilities with many industry, academic and non-profit partners and is active in a variety of networks such as the AMR Accelerator that is part of the EU\u2019s Innovative Medicines Initiative (\u201cIMI\u201d).\n<\/p>\n

\nReferences
\n
<\/b>1<\/sup> https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(21)02724-0\/fulltext#seccestitle10<\/span><\/a>
<\/span>2<\/sup> https:\/\/amr-review.org\/sites\/default\/files\/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf<\/span><\/a>\n<\/p>\n

\nPlease click on the following link for \u2018Notes to Editors\u2019 and \u2018References\u2019:\n<\/p>\n

\nhttps:\/\/www.boehringer-ingelheim.com\/media-overview\/press-releases\/joint-venture-fight-antimicrobial-resistance<\/span><\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nBoehringer Ingelheim<\/b>
Corporate Affairs<\/b>
Harro Ten Wolde<\/b>
55216 Ingelheim
\n
Phone: +49 151 61901069
\n
Email: press@boehringer-ingelheim.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

INGELHEIM, Germany & HAMBURG, Germany & MARCY-L\u2019\u00c9TOILE, France–(BUSINESS WIRE)–Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX\/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and bioM\u00e9rieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45842","6":"format-standard","7":"category-industry"},"yoast_head":"\nBoehringer Ingelheim, Evotec and bioM\u00e9rieux launch Aurobac, a joint venture to fight Antimicrobial Resistance - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim, Evotec and bioM\u00e9rieux launch Aurobac, a joint venture to fight Antimicrobial Resistance - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"INGELHEIM, Germany & HAMBURG, Germany & MARCY-L\u2019\u00c9TOILE, France–(BUSINESS WIRE)–Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX\/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and bioM\u00e9rieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-06T06:01:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220705005880\/en\/648602\/21\/BI_Logo_sw.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Boehringer Ingelheim, Evotec and bioM\u00e9rieux launch Aurobac, a joint venture to fight Antimicrobial Resistance\",\"datePublished\":\"2022-07-06T06:01:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\\\/\"},\"wordCount\":771,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220705005880\\\/en\\\/648602\\\/21\\\/BI_Logo_sw.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\\\/\",\"name\":\"Boehringer Ingelheim, Evotec and bioM\u00e9rieux launch Aurobac, a joint venture to fight Antimicrobial Resistance - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220705005880\\\/en\\\/648602\\\/21\\\/BI_Logo_sw.jpg\",\"datePublished\":\"2022-07-06T06:01:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220705005880\\\/en\\\/648602\\\/21\\\/BI_Logo_sw.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220705005880\\\/en\\\/648602\\\/21\\\/BI_Logo_sw.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim, Evotec and bioM\u00e9rieux launch Aurobac, a joint venture to fight Antimicrobial Resistance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim, Evotec and bioM\u00e9rieux launch Aurobac, a joint venture to fight Antimicrobial Resistance - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim, Evotec and bioM\u00e9rieux launch Aurobac, a joint venture to fight Antimicrobial Resistance - Pharma Trend","og_description":"INGELHEIM, Germany & HAMBURG, Germany & MARCY-L\u2019\u00c9TOILE, France–(BUSINESS WIRE)–Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX\/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and bioM\u00e9rieux, a world leader in in vitro diagnostics, announced today that they have formed a joint venture to create the next generation of antimicrobials ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-06T06:01:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220705005880\/en\/648602\/21\/BI_Logo_sw.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Boehringer Ingelheim, Evotec and bioM\u00e9rieux launch Aurobac, a joint venture to fight Antimicrobial Resistance","datePublished":"2022-07-06T06:01:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/"},"wordCount":771,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220705005880\/en\/648602\/21\/BI_Logo_sw.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/","url":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/","name":"Boehringer Ingelheim, Evotec and bioM\u00e9rieux launch Aurobac, a joint venture to fight Antimicrobial Resistance - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220705005880\/en\/648602\/21\/BI_Logo_sw.jpg","datePublished":"2022-07-06T06:01:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220705005880\/en\/648602\/21\/BI_Logo_sw.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220705005880\/en\/648602\/21\/BI_Logo_sw.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/boehringer-ingelheim-evotec-and-biomerieux-launch-aurobac-a-joint-venture-to-fight-antimicrobial-resistance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim, Evotec and bioM\u00e9rieux launch Aurobac, a joint venture to fight Antimicrobial Resistance"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45842"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45842\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45842"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45842"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}